Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q7AW
|
|||
| Former ID |
DNC011889
|
|||
| Drug Name |
IMIRESTAT
|
|||
| Synonyms |
Imirestat; 89391-50-4; Imirestat [INN]; Alcon 1576; HOE 843; Imirestatum [INN-Latin]; Hoe-843; UNII-0PM69S95UQ; AL 1576; C15H8F2N2O2; AL-1576; 0PM69S95UQ; CHEMBL269455; 2,7-Difluorospiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione; Imirestatum; 2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione; Spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione, 2,7-difluoro-; Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2,7-difluoro-; AL-theta-1576; ALO1576; AL1576; SCHEMBL49034; ZINC3724; AC1L23Q8; DTXSID80237635
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Discontinued in Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H8F2N2O2
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1F)C3(C4=C2C=CC(=C4)F)C(=O)NC(=O)N3
|
|||
| InChI |
1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)
|
|||
| InChIKey |
QCCHBHSAIQIQGO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 89391-50-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Target Info | Inhibitor | [2] |
| BioCyc | Methylglyoxal degradation III | |||
| Acetone degradation I (to methylglyoxal) | ||||
| KEGG Pathway | Pentose and glucuronate interconversions | |||
| Fructose and mannose metabolism | ||||
| Galactose metabolism | ||||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pyruvate Metabolism | ||||
| Pterine Biosynthesis | ||||
| Glycerolipid Metabolism | ||||
| Galactose Metabolism | ||||
| WikiPathways | Metapathway biotransformation | |||
| Polyol Pathway | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000020) | |||
| REF 2 | Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors. J Med Chem. 1991 Nov;34(11):3229-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.